Stockscreener 앱 받기
6.31
2.62%
-0.17
Bausch Health Companies Inc 주식(BHC)의 최신 뉴스
What analysts say about Bausch Health Companies Inc. stockFree Investment Timing Strategies - Jammu Links News
What drives Bausch Health Companies Inc. stock priceRemarkable growth - Jammu Links News
Is Bausch Health Companies Inc. a good long term investmentPhenomenal returns - Jammu Links News
Best Stock to Buy Right Now: Bausch Health vs Canopy Growth? - The Motley Fool Canada
Bausch Health Faces Patent Drama And Policy Questions This Quarter - Finimize
Bausch Health's Xifaxan Patent Clarity, Policy Commentary in Focus for Q2, RBC Says - MarketScreener
In the Wake of Bausch Health Companies Inc.'s (NYSE:BHC) Latest US$196m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions - 富途牛牛
In the wake of Bausch Health Companies Inc.'s (NYSE:BHC) latest US$196m market cap drop, institutional owners may be forced to take severe actions - simplywall.st
Amblyopia Market Growth Expected to See Next Level with Novartis - openPR.com
Bausch Health Companies (BHC) Canada Announces Expanded Availability of CABTREO Gel - Yahoo Finance
Icahn Enterprises shares rise 5.72% intraday after Bausch Health appoints new Chief Accounting Officer. - AInvest
Bausch Health's Strategic Leadership Shift: Steven Lee's Expertise Could Propel Valuation Growth Amid Transformation - AInvest
First-Ever Triple-Combination Acne Treatment CABTREO Expands Access Across Canadian Health Programs - Stock Titan
Bausch Health Names Steven Lee Chief Accounting Officer - MarketScreener
Bausch Health Appoints New Chief Accounting Officer - MarketScreener
Bausch Health Strengthens Finance Team: M&A Expert Steven Lee Takes Chief Accounting Officer Role - Stock Titan
Groundbreaking Triple-Combination Acne Treatment Expands Access Across Canadian Healthcare System - Stock Titan
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs - Yahoo Finance
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence - standard-journal.com
First FDA-Approved Drug Xifaxan Unveils Powerful Patient Stories in New Hepatic Encephalopathy Campaign - Stock Titan
SHAREHOLDER ALERT: Potential Recovery for Bausch Health Companies Inc. (BHC) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Bausch Health Companies Reaches Analyst Target Price - Nasdaq
August 22nd Options Now Available For Bausch Health Companies (BHC) - Nasdaq
Stocks In Play: Bausch Health Companies - Barchart.com
Bausch Health to Announce Second Quarter 2025 Results on July 30 - Corsicana Daily Sun
Bausch + Lomb's Dry Eye Campaign: A Strategic Opportunity in Growing Eye Health Markets - AInvest
BHC SEC FilingsBausch Health Companies Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Bausch + Lomb Brief: Closes Upsized 675 Million Euro Senior Secured Notes Offering and Partial Credit Agreement Refinancing - MarketScreener
Fed. Circ. Revives MSN Challenge To Bausch IBS Drug Patent - Law360
Bausch + Lomb Brief: Prices Upsized Senior Secured Notes Offering - MarketScreener
GMS Posts Upbeat Earnings, Joins Coinbase Global, Genworth Financial, Sandisk And Other Big Stocks Moving Higher On Wednesday - Benzinga
Bausch Health ticks higher following large director stock purchase - MSN
John Paulson buying at Bausch Health Companies (BHC) - The Globe and Mail
Bausch Health Companies: Insider Confidence Fuels Undervalued Stock's Turnaround Potential - AInvest
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference - The Globe and Mail
Director buying at Bausch Health Companies (BHC) - The Globe and Mail
Bausch Health: Repricing Potential Driven By Deleveraging (NYSE:BHC) - Seeking Alpha
Bausch Health Companies Inc. (TSE:BHC) Director John Paulson Acquires 754,134 Shares - MarketBeat
Bausch Health (BHC) Jumps 8.5% as Exec Hikes Stake; Subsidiaries Raise Over $3-Billion Fresh Funds - MSN
LOOK: These 10 Stocks Just Stole The Show - Insider Monkey
Bausch Health (BHC) Rises After Director's $15M Share Purchase - GuruFocus
Bausch Health Companies Stock Price, Quotes and Forecasts | NYSE:BHC - Benzinga
Hedge Fund and Insider Trading News: Philippe Laffont, Warren Buffett, Bill Ackman, Farallon Capital, Bausch Health Companies Inc (BHC), MicroStrategy Inc (MSTR), and More - Insider Monkey
Rising Demand in Traveler's Diarrhea MarketTop Developments, - openPR.com
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets - The Globe and Mail
Benzodiazepine Drugs Market Trends, Growth Forecast, and Top - openPR.com
Bausch + Lomb Launching Senior Secured Notes Offering and Refinancing Credit Agreement - marketscreener.com
Bausch + Lomb Brief: Launching Senior Secured Notes Offering and Refinancing Credit Agreement - marketscreener.com
Huntington's Disease Market Grows with Increased Genetic - openPR.com
Reconstructive Surgery Market Trends, Size & Growth Forecast - openPR.com
The most oversold and overbought stocks on the TSX - The Globe and Mail
4.65%
자본화:
|
볼륨(24시간):